In short
Tominersen is an investigational drug being studied for its potential in treating Huntington's Disease, a genetic disorder that affects movement, thinking, and behavior. This article explores the ongoing clinical trial, GENERATION HD2, which aims to assess the safety, effectiveness, and biological effects of Tominersen in people with early-stage Huntington's Disease.
At a glance
- Study Name
- GENERATION HD2
- Drug
- Tominersen
- Condition
- Huntington's Disease (prodromal and early manifest)
- Administration
- Intrathecal, every 16 weeks
- Dosages
- 60 mg and 100 mg
- Study Duration
- Approximately 24 months
- Primary Outcomes
- Safety, CSF composition, brain structure changes, mHTT levels, functional capacity
- Secondary Outcomes
- Cognitive function, motor skills, CSF NfL levels, anti-drug antibodies
What is Tominersen?
Tominersen is an investigational drug being studied as a potential treatment for Huntington's Disease. It is currently undergoing clinical trials to evaluate its safety and effectiveness in patients with early stages of the disease.
Target Condition: Huntington's Disease
Huntington's Disease is a genetic disorder that causes progressive brain damage. It affects movement, thinking, and emotions. The disease typically appears in adulthood and worsens over time. Tominersen is being tested in people with prodromal (early signs) and early manifest (beginning stages) Huntington's Disease.
The GENERATION HD2 Clinical Trial
The GENERATION HD2 study is a clinical trial designed to test Tominersen. Here are some key points about the trial:
- Phase II study: This means it's testing the drug in a larger group of people after initial safety studies.
- Randomized: Participants are randomly assigned to different groups.
- Double-blind: Neither the participants nor the researchers know who is receiving the actual drug or a placebo.
- Placebo-controlled: Some participants receive a placebo (a substance with no active ingredients) for comparison.
- Dose-finding: The study is testing different doses of Tominersen to find the most effective and safe dose.
How is Tominersen Administered?
Tominersen is given through an intrathecal injection, which means it's injected directly into the fluid surrounding the brain and spinal cord. The study is testing two different doses:
- 60 mg of Tominersen every 16 weeks
- 100 mg of Tominersen every 16 weeks
Some participants will receive a placebo injection that looks the same but contains no active drug.
Safety Monitoring
The study closely monitors the safety of Tominersen. This includes:
- Tracking adverse events (side effects) and their severity
- Monitoring changes in cerebrospinal fluid (the fluid around the brain and spinal cord), including white blood cell count and protein levels
- Regular brain scans (MRI) to check for any changes or abnormalities
- Assessing suicide risk using a tool called the C-SSRS (Columbia-Suicide Severity Rating Scale)
Efficacy Measures
To determine if Tominersen is effective, the study uses several tests and scales:
- Composite Unified Huntington's Disease Rating Scale (cUHDRS): A combined measure of various Huntington's Disease symptoms
- Total Functional Capacity (TFC) Scale: Measures a person's ability to perform daily activities
- Montreal Cognitive Assessment (MoCA): A test of cognitive function
- Symbol Digit Modalities Test (SDMT): Assesses processing speed and working memory
- Stroop Word Reading (SWR) Test: Measures attention and cognitive flexibility
- Total Motor Score (TMS): Evaluates movement-related symptoms
Biomarker Assessments
The study also looks at biological markers (biomarkers) to understand how Tominersen affects the disease at a molecular level:
- CSF mHTT protein levels: Measures the amount of mutant huntingtin protein, which is believed to cause Huntington's Disease
- CSF Neurofilament Light Chain (NfL) levels: An indicator of nerve cell damage
- Anti-drug antibodies (ADAs): Checks if the body is developing an immune response to the drug